Category Archives: Global

Witty Touts GSK Pipeline in 4th Quarter Review

By Reid Paul | Published: February 10, 2012
brightcove.createExperiences();
Also posted in Emerging Markets, Europe, News, R&D, Strategy | Tagged , , , , , , | Leave a comment

Fighting Tropical Disease: It's Now a Common Cause

By Guest Blogger | Published: February 8, 2012
David Torstensson, Senior Consultant, Pugatch Consilium, considers what the London Declaration on Neglected Tropical Diseases reveals about research and development efforts into neglected and tropical diseases. Last week, the Gates Foundation, several government aid agencies, the World Health Organization [WHO], and a host of  biopharm companies including GSK, Merck, Eisai, J&J, Sanofi, Novartis, Bayer and Abbott, [...]
Also posted in Guest Blog, R&D, healthcare | Tagged , , , | Leave a comment

ePharma Summit: Less Proselytizing, More Results

By Ben Comer | Published: February 7, 2012
At the digital marketing-focused ePharma Summit in New York this week, many of the problems and frustrations related to the “big three” – Facebook, Twitter and YouTube – were hashed out for umpteenth time.
Also posted in Advertising, E-Media, Events, Marketing, Regulatory, Strategy, patient education, social media | Tagged , , , , | 1 Comment

Unmet Need in the Migraine Space?

By Ben Comer | Published: February 3, 2012
Allergan CEO David Pyott is bullish on Botox’s potential as a salve for chronic migraine. He’s also betting on a next-gen dihydroergotamine (DHE) – Levadex – from MAP Pharmaceuticals.
Also posted in FDA, Marketing, Regulatory, Strategy, Technology | Tagged , , , , | 2 Comments

Roche Ups the Stakes on Personalized Medicine

By Guest Blogger | Published: February 1, 2012
By Patricia Van Arnum, Pharmaceutical Technology. Personalized medicine, which targets individualized treatment and care based on personal and genetic variations, holds much promise for the pharmaceutical industry. Several pharmaceutical majors continue to invest in this emerging field as evident by Roche’s $5.7-billion bid last week for Illumina, a provider of gene-sequencing tools and related analytics.
Also posted in Biotech, Europe, Guest Blog | Tagged , , | 1 Comment